Last updated: August 15, 2026

Application No. 17/273,680

Methods of Treating Cancer

Non-Final OA

Filed

Mar 04, 2021

Priority

Sep 04, 2018 — provisional 62/726,826 +1 more

Examiner

LANDSMAN, ROBERT S

Art Unit

1647

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

Tesaro Inc.

OA Round

3 (Non-Final)

Interview Optional

— +13.3% interview lift. Interview lift (+13.3%) is below the 15.0% threshold. A written response is recommended.

Based on 1268 resolved cases, 2023–2026

Examiner Intelligence

LANDSMAN, ROBERT S View full profile →

Grants 81% — above average

Career Allowance Rate

1031 granted / 1268 resolved

+21.3% vs TC avg

Moderate +13% lift

Without

With

+13.3%

Interview Lift

resolved cases with interview

Fast prosecutor

2y 2m

Avg Prosecution

52 currently pending

Career history

1298

Total Applications

across all art units

Statute-Specific Performance

§101

3.6%

-36.4% vs TC avg

§103

19.5%

-20.5% vs TC avg

§102

13.4%

-26.6% vs TC avg

§112

40.2%

+0.2% vs TC avg

Black line = Tech Center average estimate • Based on career data from 1268 resolved cases

Prosecution Timeline

Mar 04, 2021

Application Filed

Jan 23, 2024

Non-Final Rejection mailed

May 29, 2024

Response Filed

Apr 18, 2025

Final Rejection mailed

Sep 18, 2025

Request for Continued Examination

Sep 25, 2025

Response after Non-Final Action

Jul 29, 2026

Non-Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

18/258,858

Patent 12703752

MULTISPECIFIC ANTIBODIES HAVING SPECIFICITY FOR IL-4R AND IL-31

3y 1m to grant Granted Aug 11, 2026

17/914,685

Patent 12697351

Inhibitors of C5a for the Treatment of Corona Virus Infection

3y 10m to grant Granted Aug 04, 2026

18/060,814

Patent 12698321

ANTIBODIES FOR CORONAVIRUS AND USES THEREOF

3y 8m to grant Granted Aug 04, 2026

17/642,488

Patent 12674001

BISPECIFIC ANTIBODIES BINDING TO 5T4 AND CD3 FOR USE IN TREATMENT OF CANCER

4y 3m to grant Granted Jul 07, 2026

19/302,560

Patent 12662545

MUSCLE-TARGETING COMPLEXES AND USES THEREOF

10m to grant Granted Jun 23, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4

Expected OA Rounds

81%

Grant Probability

95%

With Interview (+13.3%)

2y 2m (~0m remaining)

Median Time to Grant

High

PTA Risk

Based on 1268 resolved cases by this examiner. Grant probability derived from career allowance rate.